Antibe Therapeutics Inc(Pre-Merger) ATBPF

Healthcare Biotechnology

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.

GREY:ATBPF - Post by User

Antibe Therapeutics Inc(Pre-Merger)

Bullboard Posts

Comment by funky99on Apr 20, 2016 9:37am

141 Views

Post# 24787987

RE:RE:RE:I am out..too little too la

Nothing happens within a day in the biotech/healthcare space and clinical trial are expensive. I think Antibe Therapeutcs has been hitting milestones nicely and building a nice company so far. I originally invested in the potential of ATB-346 based on the long history of research data and like it more now as a growth company that will help them fund their clinical trial and added to my position.

I like the people involved and experience on the Board of directors and Leadership.

Knight Therapeutics is involved and Bloom Burton Healthcare Fund. The CEO of Knight Therapeutics was on the board of director of Antibe and they already securied rights and a deal. I you read on Knight Therapeutics (ex Paladin Labs) you will notice they had a pool of 100 investment/deal biotech`healthcare opportunities to build their pipeline of drugs, only a few were selected an Antibe Therapeutics is one of them. To me this bodes really well to the future of Antibe Therapeutics.

Antibe Therapeutics will be presenting at Bloom Burton Healthcare conference in May 2016.

They now have a pipeline of drug and revenue. Compared to pears in the industry it should trade at higher than 1x sales andt it does not even include all the potential of the drugs.

Upcoming Milestones per investor presentation :

Antibe’s pipeline has several potential catalysts over the next 18 months, including initial Phase 2 data from ATB-346 by Q3/16.